Inventor

HASTINGS MICHELLE L

US13 patents

⚠️ This page may combine multiple inventors who share the name “HASTINGS MICHELLE L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE

9 patents

US9840709B2Dec 12, 2017

Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE6 citations69

US12042508B2Jul 23, 2024

Antisense compounds targeting genes associated with cystic fibrosis

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE0 citations60

US9556434B2Jan 31, 2017

Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for usher syndrome

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE0 citations50

US10787669B2Sep 29, 2020

Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE0 citations48

US10370667B2Aug 6, 2019

Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE0 citations48

IONIS PHARMACEUTICALS INC

2 patents

US11732260B2Aug 22, 2023

Compounds and methods for the modulation of amyloid-β precursor protein

IONIS PHARMACEUTICALS INC2 citations72

US10472634B2Nov 12, 2019

Antisense compounds targeting apolipoprotein E receptor 2

IONIS PHARMACEUTICALS INC0 citations51

HASTINGS MICHELLE L

2 patents

US9353371B2May 31, 2016

Antisense compounds targeting genes associated with usher syndrome

HASTINGS MICHELLE L5 citations70

US8648053B2Feb 11, 2014

Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome

HASTINGS MICHELLE L2 citations58